Meta analysis of efficacy of pegylated interferon versus common interferon in the treatment of HBeAg positive chronic hepatitis B
Fang-zhou JIAO,Hai-yue ZHANG,Fei-fei LIU,Lv-wen WANG,Zuo-jiong GONG
DOI: https://doi.org/10.3969/j.issn.1003-6350.2017.08.055
2017-01-01
Abstract:Objective To evaluate the efficacy of pegylated interferon (PEG-IFN-ɑ-2a or PEG-IFN-ɑ-2b) and common interferon in the treatment of HBeAg positive chronic hepatitis B. Methods Randomized controlled trials (RCTs) about the efficacy comparison between pegylated interferon (PEG-IFN-ɑ-2a or PEG-IFN-ɑ-2b) and common in-terferon for the treatment of HBeAg positive chronic hepatitis B before July 1st , 2016 were searched from Medline, Em-base, EBSCO, Chinese Biomedical Literature Database (CBM), VIP, CNKI and Wanfang database. The references of the obtained literatures were also traced. Mate-analysis was performed by using RevMan 5.2 software after two researchers screened literature independently, extracted data and assessed the risk of bias. Results Thirteen RCTs (n=1263) were involved, including 616 cases in Pegylated interferon group and 647 cases in common interferon group. The results of meta-analysis showed that at 24 week and 48 week, the ALT normalization, HBV-DNA negative conversion rate and HBeAg negative conversion rate in Pegylated interferon group were significantly higher than those in common interfer-on group (P<0.05). At 12 week, HBV-DNA negative conversion rate in Pegylated interferon group was higher than that in common interferon group (Z=2.19,P=0.03), but there were no statistical differences in ALT normalization and HBeAg negative conversion rate between Pegylated interferon group and common interferon group (P>0.05). At 12 week and 24 week, there was no statistical difference in the HBsAg negative conversion rate between the two groups (P>0.05), but at 48 week, HBsAg negative conversion rate in Pegylated interferon group was higher than that in common in-terferon group (Z=2.34, P=0.02). At 12 week and 48 week, there was no statistical difference in the HBeAg seroconver-sion rate between Pegylated interferon group and common interferon group (P>0.05), however, that in the Pegylated in-terferon group was higher than common interferon group at 24 week (Z=2.90, P=0.004). Conclusion After the treat-ment for 24 weeks and 48 weeks, Pegylated interferon (PEG-IFN-ɑ-2a or PEG-IFN-ɑ-2b) was superior to common in-terferon in ALT normalization, HBV-DNA negative conversion rate, HBeAg negative conversion rate. At 48 week, only HBsAg negative conversion rate in Pegylated interferon group was higher than that in common interferon group, and at 24 week, only HBeAg seroconversion rate in Pegylated interferon group was higher than common interferon. Due to the quantity and quality limitations of included studies, more high quality studies are needed to verify the above conclusions.